Vancouver, British Columbia--(Newsfile Corp. - July 15, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), is pleased to announce that further to its news release dated June 11, 2026, it has closed its previously announced non-brokered private placement of common shares in the capital of the Company (the "Shares") at a price of $0.50 per Share under the Listed Issuer Financing Exemption (as defined herein) for gross proceeds of $2,000,000 (the "LIFE Offering") through the issuance of 4,000,000 Shares.
Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus Exemptions ("NI 45-106"), the LIFE Offering was made to purchasers resident in all provinces of Canada, except Quebec, pursuant to the listed issuer financing exemption under Part 5A of NI 45-106 (the "Listed Issuer Financing Exemption"). The securities offered under the Listed Issuer Financing Exemption are not subject to a hold period in accordance with applicable Canadian securities laws.
In connection with the LIFE Offering, the Company did not pay any finders fees.
The Company intends to use the net proceeds from the Offering for general working capital purposes, to advance its business objectives, fund marketing initiatives and support the procurement of inventory and products.
The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
About The Precision Peptide Company
The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) is a publicly traded wellness company focused on advanced peptide formulations and delivery systems. The Company is building a next-generation wellness platform that combines scientific formulation, sustainable sourcing, and innovative delivery systems, creating products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.
For more information, visit: www.precisionpeptidecompany.com